TrialEuropean journal of nuclear medicine and molecular imaging2015

Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.

Raghava Kashyap et al.PubMed ↗Publisher ↗

No numbers read from the abstract.